Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received a consensus recommendation of "Hold" from the nine research firms that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.24.

A number of research firms recently commented on ZNTL. Wedbush reaffirmed a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Finally, HC Wainwright reduced their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, January 29th.

Insider Buying and Selling

In related news, Director Jan Skvarka acquired 60,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the purchase, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ingmar Bruns bought 20,000 shares of the firm's stock in a transaction on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now owns 36,629 shares of the company's stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of ZNTL. Almitas Capital LLC increased its holdings in Zentalis Pharmaceuticals by 69.3% in the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock worth $4,929,000 after purchasing an additional 665,968 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of Zentalis Pharmaceuticals by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock valued at $4,608,000 after buying an additional 22,600 shares during the period. Verition Fund Management LLC raised its holdings in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock valued at $5,536,000 after buying an additional 951,500 shares during the last quarter. Geode Capital Management LLC boosted its position in Zentalis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock worth $3,979,000 after buying an additional 20,864 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its holdings in Zentalis Pharmaceuticals by 9.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company's stock worth $3,756,000 after acquiring an additional 110,882 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL traded up $0.11 on Friday, reaching $1.95. The stock had a trading volume of 587,692 shares, compared to its average volume of 2,031,089. The company has a market cap of $138.82 million, a P/E ratio of -0.79 and a beta of 1.75. The firm has a fifty day moving average of $2.29 and a two-hundred day moving average of $2.98. Zentalis Pharmaceuticals has a 1-year low of $1.61 and a 1-year high of $16.27.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.